Bookmark! (press Ctrl+D)

Subscribe to our channel!

Results from early-stage clinical trials of Russia’s ‘Sputnik V’ COVID-19 vaccine, published in The Lancet medical journal, show “Russia’s leadership in creating a vaccine against coronavirus”, CEO of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev stated in Moscow on Friday.

“The journal published that there were no serious consequences on volunteers who took the vaccine. There was also a very strong autoimmune response due to the creation of antibodies,” Dmitriev stated.

He said that Russia’s two-shot injectable vaccine “shows better results and more effective results than Western vaccines.”

The CEO also pointed out that countries from Latin America, the Middle East, and Asia had already showed interest in ‘Sputnik V’.

The first batches of the vaccine were delivered to three Moscow clinics on Friday to begin voluntary trial vaccination in the capital.

According to a study published in The Lancet journal, the trials of ‘Sputnik V’ discovered that all 76 participants in the early-stage trials developed antibodies, and none showed any significant side effects.

Video ID: 20200904-044

Video on Demand:




Please enter your comment!
Please enter your name here